Cromoglicate in Mastocytosis

Mastocytosis Clinical Trial

Official title:

A Phase II Exploratory Study Evaluating the Efficacy of Topical Cromoglicate Solution Compared to Topical Solution Vehicle in the Treatment of Mastocytosis

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01701843
• Other study ID #: LP0074-33
• Status: Terminated
• Phase: Phase 2
• First received: July 11, 2012
• Last updated: March 6, 2013
• Start date: October 2012
• Est. completion date: February 2013

Study information

• Verified date: March 2013
• Source: LEO Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The purpose of this exploratory study is to investigate the clinical efficacy of study drug (LP0074) in the treatment of Mastocytosis. The trial will be performed as a left/right comparison study in male/female subjects with mastocytosis, in a prospective, double-blinded, randomised, single centre setting.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 7
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Signed informed consent has been obtained

• Chronic stable symptomatic maculopapulous cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement and a positive Darier's Sign

• Age between 18 and 70 years

• Either sex

• Any race or ethnicity

• Attending hospital outpatient clinic or the private practice of a dermatologist.

Exclusion Criteria:

• The presence of autoimmune and infectious disease including aggressive systemic mastocytosis

• Medical history or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia

• Medical history or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy, hyper/hypokalemia

• Evidence of severe renal dysfunction (creatinine > 1,5 times upper reference value)

• Evidence of significant hepatic disease (liver enzymes > 2 times upper reference value)

• Presence of active cancer which requires chemotherapy or radiation therapy

• Commitment to an institution in terms of § 40 Abs. 1 S. 3 Nr. 4 AMG

• Intake of antihistamines or leukotriene antagonists within 7 days prior to the beginning of the study

• Intake of oral corticosteroids within 14 days prior to randomisation

• Use of depot corticosteroids or chronic systemic corticosteroids within 21 days prior to randomisation

• Radiation therapy of target areas including UV therapy within 4 weeks prior to randomisation

• Confounding other dermatological diseases or conditions that can affect the symptoms of the target areas

• Known or suspected hypersensitivity to component(s) of investigational products.

• Current participation in any other interventional clinical trial.

• Subjects who have received treatment with any nonmarketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within the last 4 weeks or 5 half-lives (whichever is longer) prior to randomisation

• Previously randomised in this clinical trial

• In the opinion of the investigator, the subject is unlikely to comply with the Clinical Study Protocol (e.g. alcoholism, drug dependency or psychotic state).

• Females who are pregnant, of child-bearing potential and wishing to become pregnant during the trial or are breast feeding.

• Females of child-bearing potential with positive pregnancy test at visit 1.

• Subjects (or their partner) not using an adequate method of contraception (according to national requirements, as applicable)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Mastocytosis

Intervention

Drug:
• Cromoglicate
Twice daily topical treatment for 14 days
• Placebo
Twice daily topical treatment for 14 days

Locations

Country	Name	City	State
Germany	Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
LEO Pharma

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of mechanically induced changes of lesions		Baseline to week 2	No
Secondary	Evaluation of mechanically induced wheal and flare response		Baseline to week 2	No